INS and chronic kidney disease: Our analysis of the data from CREDENCE adds to the existing literature, extending previous findings to people with established CKD, demonstrating consistency of effects across a spectrum of eGFR and UACR, as well as quantifying the likelihood of achieving clinically meaningful reductions in insulin dose.